Scolaris Content Display Scolaris Content Display

Cochrane Database of Systematic Reviews

Anti‐IgE therapy for allergic bronchopulmonary aspergillosis in people with cystic fibrosis

Information

DOI:
https://doi.org/10.1002/14651858.CD010288.pub5Copy DOI
Database:
  1. Cochrane Database of Systematic Reviews
Version published:
  1. 22 September 2021see what's new
Type:
  1. Intervention
Stage:
  1. Review
Cochrane Editorial Group:
  1. Cochrane Cystic Fibrosis and Genetic Disorders Group

Copyright:
  1. Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Article metrics

Altmetric:

Cited by:

Cited 0 times via Crossref Cited-by Linking

Collapse

Authors

  • Kana R Jat

    Correspondence to: Department of Pediatrics, All India Institute of Medical Sciences (AIIMS), New Delhi, India

    [email protected]

  • Dinesh K Walia

    Department of Community Medicine, Govt. Medical College and Hospital (GMCH), Chandigarh, India

  • Anju Khairwa

    Department of Pathology, University College of Medical Sciences (UCMS), Delhi, India

Contributions of authors

 Roles and responsibilities

Task

Who will undertake the task?

Protocol stage: draft the protocol

All three authors

Review stage: select which trials to include (2 + 1 arbiter)

All three authors

Review stage: extract data from trials (2 people)

KRJ, AK

Review stage: enter data into RevMan

KRJ, AK

Review stage: carry out the analysis

KRJ, DKW

Review stage: interpret the analysis

All three authors

Review stage: draft the final review

All three authors

Update stage: update the review

All three authors

Sources of support

Internal sources

  • All India Institute of Medical Sciences, New Delhi, India

    Support from library regarding literature search and getting full text articles.

External sources

  • National Institute for Health Research, UK

    This systematic review was supported by the National Institute for Health Research, via Cochrane Infrastructure funding to the Cochrane Cystic Fibrosis and Genetic Disorders Group.

Declarations of interest

All authors: none known.

Acknowledgements

We thank Nikki Jahnke for support in drafting the review.

This project was supported by the National Institute for Health Research, via Cochrane Infrastructure funding to the Cochrane Cystic Fibrosis and Genetic Disorders Group. The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the Systematic Reviews Programme, NIHR, NHS or the Department of Health.

Version history

Published

Title

Stage

Authors

Version

2021 Sep 22

Anti‐IgE therapy for allergic bronchopulmonary aspergillosis in people with cystic fibrosis

Review

Kana R Jat, Dinesh K Walia, Anju Khairwa

https://doi.org/10.1002/14651858.CD010288.pub5

2018 Mar 18

Anti‐IgE therapy for allergic bronchopulmonary aspergillosis in people with cystic fibrosis

Review

Kana R Jat, Dinesh K Walia, Anju Khairwa

https://doi.org/10.1002/14651858.CD010288.pub4

2015 Nov 04

Anti‐IgE therapy for allergic bronchopulmonary aspergillosis in people with cystic fibrosis

Review

Kana R Jat, Dinesh K Walia, Anju Khairwa

https://doi.org/10.1002/14651858.CD010288.pub3

2013 Sep 17

Anti‐IgE therapy for allergic bronchopulmonary aspergillosis in people with cystic fibrosis

Review

Kana R Jat, Dinesh K Walia, Anju Khairwa

https://doi.org/10.1002/14651858.CD010288.pub2

2012 Dec 12

Anti‐IgE therapy for allergic bronchopulmonary aspergillosis in people with cystic fibrosis

Protocol

Kana R Jat, Dinesh K Walia, Anju Khairwa

https://doi.org/10.1002/14651858.CD010288

Differences between protocol and review

In line with current guidance, we have added plans for summary of findings tables to the Methods section.

Notes

None.

Keywords

MeSH

PICOs

Population
Intervention
Comparison
Outcome

The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.

See more on using PICO in the Cochrane Handbook.

Study flow diagram.

Figures and Tables -
Figure 1

Study flow diagram.

Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.

Figures and Tables -
Figure 2

Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.

Risk of bias summary: review authors' judgements about each risk of bias item for each included study.

Figures and Tables -
Figure 3

Risk of bias summary: review authors' judgements about each risk of bias item for each included study.

Table 1. Adverse effects in included trial

AEs

Omalizumab group

N = 9, n (%)

Placebo group

N = 5, n (%)

Non‐serious AEs

Participants with AE(s)

9 (100)

5 (100)

Infective pulmonary exacerbation of CF

7 (78)

4 (80)

Cough

4 (44)

1 (20)

Headache

4 (44)

1 (20)

Pyrexia

3 (33)

2 (40)

Hemoptysis (blood in sputum)

4 (44)

0

Injection site swelling

4 (44)

0

Injection site warmth

4 (44)

0

Injection site erythema (redness)

3 (33)

0

Hypokalemia

2 (22)

0

Nasopharyngitis

2 (22)

0

Sputum increased

1 (11)

1 (20)

Bronchopulmonary aspergillosis allergic

2 (22)

0

Rhonchi (noisy expiratory breathing sound)

1 (11)

1 (20)

Non‐cardiac chest pain

1 (11)

1 (20)

Vomiting

0

1 (20)

SAEs

Participants with any SAE

6 (67)

1 (20)

Infective pulmonary exacerbation of CF

5 (56)

1 (20)

Allergic Bronchopulmonary Aspergillosis

2 (22)

0

Distal intestinal obstruction syndrome

1 (11)

0

Hemoptysis

1 (11)

0

Rhonchi

1 (11)

0

AE: adverse event
CF: cystic fibrosis
SAE: serious adverse event

Figures and Tables -
Table 1. Adverse effects in included trial